R

Avita Medical
D

RCEL

8.72500
USD
-1.055
(-10.79%)
Market Closed
Volume
4,928
EPS
0
Div Yield
0
P/E
-6
Market Cap
296,152,620
OverviewSignalsIdeasNews
Related Instruments
    C
    CSTL
    -1.150
    (-4.76%)
    23.020 USD
    K
    KNSA
    -0.870
    (-3.27%)
    25.730 USD
    T
    TNDM
    -1.800
    (-4.87%)
    35.170 USD
    V
    VCEL
    -2.900
    (-5.72%)
    47.800 USD
News

Title: Avita Medical

Sector: Healthcare
Industry: Medical Devices
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.